Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro (tirzepatide) is taken as a single subcutaneous injection once every seven days. That weekly rhythm stays constant throughout treatment; the dose may increase over time, but the injection frequency never does. Because Mounjaro is a prescription-only medicine, a GPhC-registered prescriber decides both the starting dose and when any increase is appropriate — that clinical judgement cannot be replaced by a dosing chart alone.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Plenty of people start Mounjaro expecting that if one injection a week is good, two might work better. It is one of the questions our prescribers hear most weeks, and the answer is straightforward: the medicine is not designed that way, and doubling up would not double the effect. Mounjaro is formulated as a once-weekly injection precisely because tirzepatide has a half-life of roughly five days, which means a meaningful amount remains active in your body across the full week. If you want to understand how often you take the Mounjaro injection and why that schedule is set the way it is, the reasoning comes down to how long tirzepatide stays active and what the clinical programme actually tested.
The same logic applies in reverse. Taking it every ten days because life got busy is not equivalent to the licensed schedule either. Consistency matters. Picking a day that suits your routine (a Sunday evening, a Tuesday morning, whatever you will actually remember) and staying with it is genuinely important. You can use the once-weekly injection guidance to see how this plays out practically across a full month's pen.
The NHS medicines page for tirzepatide explains this schedule clearly and is worth bookmarking alongside your Patient Information Leaflet. What changes week to week, if anything, is not how often you inject but how your body is settling, and whether your prescriber decides a dose increase is warranted.
Starting at 2.5 mg is not a therapeutic punt, that first dose exists because the GI side effects of tirzepatide (nausea is the most common) are substantially easier to manage when the body gets time to adjust. The 2.5 mg pen is the system finding its footing, not the medicine working at full tilt. Most people then step up to 5 mg after four weeks, then onward through 7.5, 10, 12.5 and up to 15 mg, each step roughly a month apart.
None of those step-ups change the weekly rhythm. You still inject once every seven days. What your prescriber is adjusting is the amount of tirzepatide in each injection, not how often it lands. In the SURMOUNT-1 trial, average weight reduction at the 15 mg dose reached around 20–21% over 72 weeks, figures that came from maintaining that consistent once-weekly schedule throughout, not from any variation in frequency. The full Mounjaro overview covers the evidence behind these results.
Dose changes should only happen following a clinical review. At nume, every repeat order is assessed before it is approved, your prescriber looks at how you have been getting on, not just whether the pen is due.
Because the seven-day interval is fixed, the day you choose at the start tends to stick. A few situations are worth planning for. If you are travelling across time zones, the SmPC guidance is to maintain the same calendar day where possible; your prescriber can advise on specific scenarios. Before any surgery, tell your surgical team and anaesthetist that you are taking Mounjaro, current NHS England guidance recommends this as standard. Injections rotate between the abdomen, thigh and upper arm to prevent skin changes at any single site.
For women using oral contraceptives, there is one specific point that often gets missed: NHS guidance notes that for the first four weeks of tirzepatide treatment and for four weeks after each dose increase, a non-oral contraceptive method (such as condoms) should be added, because gastric emptying changes may affect pill absorption. This applies to Mounjaro specifically; the evidence base differs for other GLP-1 medicines. Your prescriber will cover this at consultation. If you want to understand how tirzepatide's mechanism produces these effects, that page explains the dual GIP and GLP-1 pathway in more detail.
Storage is equally fixed: the pen lives in the fridge until you are ready to use it. The manufacturer specifies a limited window during which the pen can be kept at room temperature, always check the leaflet for the exact period rather than relying on a summary. A sharps container is the correct way to dispose of used pens; your local pharmacy or GP surgery can advise on collection.
The injection frequency is not something to self-modify. If you have been unwell and vomiting around your injection day, if you have accidentally taken two pens close together, or if you are considering a longer gap because you want to take a break, these all warrant a conversation with your prescriber rather than a personal judgement call. The same goes for anything beyond mild nausea: severe stomach pain that radiates to the back, significant dehydration, or any sign of an allergic reaction should prompt contact with your GP or 111 promptly. Suspected side effects can be reported directly via the MHRA's Yellow Card scheme.
At the start of treatment, reviewing how the schedule is working is part of what makes the process clinical rather than just transactional. If you have questions about what to expect across each dose step, the FAQ section covers common ones, and the clinical team is available seven days a week for aftercare queries. For those weighing up the cost of committing to a weekly injection regimen long-term, the Mounjaro cost context page sets out what private treatment typically involves in 2025–2026. When you are ready to take the next step, check your eligibility with a free consultation, reviewed the same day by a real prescriber.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.